Neurological Immune-Related Adverse Events in Patients Treated with Anti-Programmed Death 1 Agent, Pembrolizumab: A Case Series.

ABSTRACT:

Background

This case series highlights the various clinical manifestations of pembrolizumab-induced neurological adverse events, offering insights into the spectrum of immune-related neurological adverse events associated with immune checkpoint inhibitor (ICI) therapy.

Case presentation

We present 5 patients who received pembrolizumab as a part of their treatment. They exhibited a variety of clinical manifestations, which included central nervous system involvement and necrotizing myopathy, each responding differently to therapeutic interventions. Among the participants, there were two cases of myopathy, one case of demyelinating polyneuropathy, one individual whose myasthenia gravis had worsened, and 1 patient diagnosed with encephalitis. The patients experienced symptoms w

SUBMITTER: Khosravi S 

PROVIDER: S-EPMC12274057 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature